Back to News
Market Impact: 0.15
Delve Bio Expands Metagenomic Infectious Disease Testing with Launch of Delve Detect Plasma at IDWeek 2026
Source: Business Wire
Healthcare & BiotechProduct LaunchesTechnology & Innovation
Delve Detect Plasma enables unbiased detection of more than 68,000 bacteria, fungi, DNA and RNA viruses, and parasites, with next-day results. The brief announcement provides no additional performance or commercial details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
More News
- Why is Samsung Electronics stock plunging today?
- SK Hynix plunges 8% amid Asia tech rout as Fed rate hike fears, AI funding worries mount
- Elon Musk says Trump is 'ultimately' responsible for any curbs on Ukraine's Starshield systems
- SK Hynix seeks U.S. chip equipment exports to China tied to new factory
- Dell stock plunges 11%, leading data center sell-off on concerns about 'enterprise AI timing'
- Why is Rocket Lab stock tumbling today?
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AllMind Fixed Income Compass for October 2025: Navigating Policy Divergence and Political Risk
- AI Equity Research Tools for RIAs and Wealth Managers